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The SARS-CoV-2 spike ectodomain (S-ECD) folds into a mul-
tidomain architecture (1, 2) and includes the RBD, which is 
essential for viral infectivity, and the structurally adjacent 
NTD, which plays an uncertain role. Humoral immunity to 
the spike (S) surface glycoprotein can correlate with protec-
tion, (3) and it is the primary antigenic target for most vac-
cines and monoclonal antibodies (mAbs). That the B cell 
repertoire can recognize multiple spike epitopes is supported 
by extensive single-cell cloning campaigns (4–9). However, 
the identity, abundance, and clonality of the IgG plasma an-
tibody repertoire and the epitopes it may target are not 
known (10–12). Divergence between the two repertoires is bi-
ologically plausible (13–17) and the evidence in COVID-19 in-
cludes a paradoxical disconnect between virus-neutralizing 
IgG titers and RBD-specific B cell immunity (6, 11, 18, 19). 
To analyze the IgG repertoire, blood was collected during 
early convalescence from four seroconverted study subjects 
(P1–P4) who experienced mild COVID-19 disease that 
manifested with plasma virus-neutralization titers in the low-
est quartile (P1 and P3), the second highest quartile (P2), or 
the highest quartile (P4) compared to a larger cohort (table 
S1 and fig. S1). The lineage composition and relative abun-
dance of constituent IgG antibodies comprising the plasma 
response to either intact stabilized S-ECD (S-2P (1)) or RBD 
was determined using the Ig-Seq pipeline (13, 14, 20) that in-
tegrates analytical proteomics of affinity purified IgG frac-
tions with peripheral B cell antibody variable region 
repertoires (BCR-Seq). 
IgG lineages detected by Ig-Seq in the S-ECD fraction but 
absent from the RBD fraction were deemed to be reactive 
with spike epitopes outside the RBD. In subject P3, we de-
tected six IgG lineages that bound to S-ECD (Fig. 1A). Four of 
these (Lin.1 to Lin.4) accounted for 93.5% abundance of the 
total plasma IgG S-ECD response and exhibited extensive in-
tralineage diversity (fig. S2) indicative of clonal expansion 
and selection. Notably, the top three lineages (Lin.1 to Lin.3; 
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The molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in 
blood plasma following SARS-CoV-2 infection are unknown. Proteomic deconvolution of the IgG repertoire 
to the spike glycoprotein in convalescent subjects revealed that the response is directed predominantly 
(>80%) against epitopes residing outside the receptor-binding domain (RBD). In one subject, just four IgG 
lineages accounted for 93.5% of the response, including an N-terminal domain (NTD)-directed antibody 
that was protective against lethal viral challenge. Genetic, structural, and functional characterization of a 
multi-donor class of “public” antibodies revealed an NTD epitope that is recurrently mutated among 
emerging SARS-CoV-2 variants of concern. These data show that “public” NTD-directed and other non-RBD 
plasma antibodies are prevalent and have implications for SARS-CoV-2 protection and antibody escape. 
>85% abundance) all bound to non-RBD epitopes (S2 subunit
or NTD). Bulk serology ELISAs recapitulated the Ig-Seq result
and demonstrated similarly high levels of non-RBD-binding
IgG (P>0.05) (Fig. 1B), confirming that RBD-binding plasma
antibodies comprise only a minor proportion of all spike-
binding IgG in naturally infected individuals (21). In all four
subjects, the detected plasma IgG repertoire to S-ECD was ol-
igoclonal, comprising only 6–22 lineages, with the top-ranked
lineage comprising 15 to 50% total abundance. On average,
84% of the anti-S-ECD plasma IgG repertoire bound to
epitopes outside the RBD (Fig. 1C), a finding consistent with
data from single B cell analyses (22), and the most abundant
plasma IgG lineage in all donors recognized a non-RBD
epitope (Figs. 1A and 2A and fig. S3).
Binding analysis of P3 mAbs CM29–CM32 representing 
the most expanded clones within each of lineages Lin.1 to 
Lin.4 showed that CM29 (Lin.1) recognizes the S2 subunit (KD 
= 6.6 nM), CM30 and CM31 (Lin.2 and Lin.3 with KD = 0.8 
and 37.7 nM, respectively) were specific for the NTD, and 
CM32 (Lin.4) bound the RBD (KD = 6.0 nM), as expected from 
the Ig-Seq differential affinity purifications (Fig. 1A and table 
S2). CM30 potently neutralized authentic SARS-CoV-2 in 
vitro (IC50 = 0.83 μg/ml), CM32 was slightly less potent (2.1
μg/ml), whereas CM29 and CM31 showed minimal neutrali-
zation activity (Fig. 1D). 
We then determined the capacity of mAbs CM29–CM32, 
singly and in combination, to confer prophylactic protection 
in vivo to virus challenge using the MA10 mouse model of 
SARS-CoV-2 infection (23, 24). Even though the RBD-directed 
mAb CM32 could neutralize authentic virus in vitro and had 
relatively high antibody-dependent cellular phagocytosis 
(ADCP) activity (fig. S4), it did not protect in vivo (fig. S5), 
possibly due to amino acid changes in the MA10 virus. Simi-
larly, no protection was observed for the non-neutralizing S2-
directed mAb CM29 or non-neutralizing NTD-directed mAb 
CM31. The neutralizing mAb CM30, derived from the top-
ranking NTD-targeting IgG lineage (21% abundance), was the 
sole plasma antibody that conferred complete protection to 
MA10 viral challenge (Fig. 1, E and F, and fig. S5). Interest-
ingly, administration of a cocktail comprising the top non-
RBD plasma mAbs CM29–CM31 (>85% of the IgG plasma lin-
eages to S-ECD; Fig. 1A) showed the most robust protection 
and lung viral titers below the limit of detection (LOD) in 
high viral load challenge (104 PFU). 
Subject P2, with ~10-fold higher neutralizing titer com-
pared to subject P3 (fig. S1 and table S1), displayed a more 
polyclonal IgG response (Fig. 2A), with 12/15 lineages (>80% 
total abundance) in the anti-S-ECD repertoire recognizing 
non-RBD epitopes. Conspicuously, as with P3, the most abun-
dant S-ECD-directed plasma antibodies target the S2 subunit, 
with the four topmost lineages (68% total abundance) bind-
ing to S2. MAbs CM25 and CM17, representative of two NTD-
targeting lineages each comprising ~2.5% of the response at 
day 56 (Ig-Seq Lin.6 and Lin.9) (Fig. 2A), were both encoded 
by unmutated or near-germline IGHV1-24. We found an ad-
ditional NTD-targeting unmutated IGHV1-24 plasma mAb 
(CM58) in subject P4. CM17, CM25 and CM58 bound S-ECD 
with similar single-digit nM affinity (Fig. 2B and table S2) 
and all three potently neutralized SARS-CoV-2 virus, with IC50 
values of 0.01–0.81 μg/ml comparable to S309 anti-RBD con-
trol (25) (Fig. 2C, fig. S6, and table S2). For all three mAbs, 
pre-administration in the MA10 mouse model resulted in sig-
nificantly reduced lung viral titers post-infection with 105 
PFU (Fig. 2D; P<0.001), resulting in 100% survival, compared 
to just 40% in the control group (Fig. 2E). CM17- and CM25-
treated cohorts exhibited only minimal weight loss (Fig. 2F). 
Thus, IGHV1-24 is intrinsically suited for potent and protec-
tive targeting of the NTD. 
B cell expression of IGHV1-24 in COVID-19 (~5 to 8%) (5, 
7, 26) is ~10-fold higher than healthy individuals (0.4 to 0.8%) 
(27). Moreover, we could detect IGHV1-24 plasma antibodies 
only in S-ECD fractions (mean 3.7%), but not among anti-
RBD IgGs (Fig. 3, A and B). Alignment of CM17, CM25, and 
CM58 with four neutralizing IGHV1-24 anti-NTD mAbs 
cloned from peripheral B cells [4A8 (4), 1-68 (5), 1-87 (5), 
COVA2-37 (7)] and an additional antibody [COV2-2199 (8)] 
identified a class of convergent VH immune receptor se-
quences (Fig. 3C). In all cases, three glutamate (Glu) residues 
(Glu36, Glu59, and Glu80) located in complementarity-deter-
mining region (CDR)-H1, CDR-H2, and framework H3 (FWR-
H3), respectively, as well as a phenylalanine (Phe) residue 
(Phe56) in CDR-H2, were invariably unmutated and are 
unique to the electronegative IGHV1-24 (pI=4.6). The conver-
gent VH genes paired promiscuously with six distinct light-
chain VL genes, yet CDR-H3 peptide lengths were restricted 
(14 or 21 amino acids) (Table S3). A “checkerboard” binding-
competition experiment (Fig. 3D) indicated the presence of 
at least two epitope clusters on the NTD, including one tar-
geted by all of the tested IGHV1-24 mAbs (4A8, CM25, CM17, 
CM58, and 1-68) and the IGHV3-11 mAb CM30. Another NTD 
epitope was identified by CM31 (IGHV2-5, 6.4% mutation), 
which overlapped with CM30 (IGHV3-11; 3.1% mutation), 
CM58, and 1-68 but did not compete with the other three 
IGHV1-24 NTD mAbs. 
To better understand the IGHV1-24 interactions with the 
spike NTD, we determined a cryo-EM structure of CM25 Fabs 
bound to trimeric S-ECD (Fig. 4A and figs. S7 and S8). Fo-
cused refinement of the CM25-NTD interface resulted in a 
3.5-Å reconstruction that revealed a heavy-chain–dominant 
mode of binding, with substantial contacts mediated by in-
teractions between the three CDRs and the N3 and N5 loops 
of the NTD (Fig. 4B). The light chain contributes only 11% (86 
Å2) of the total CM25 binding interface, mainly through a 
stacked hydrophobic interaction between CDR-L2 Tyr55 and 
Pro251 within the N5 loop. Unique germline IGHV1-24 resi-
dues contribute 20% (149 Å2) of the total binding interface. 
CDR-H1 interacts extensively through hydrogen bonds and 
contacts between hydrophobic residues, including a salt 
bridge formed between the conserved Glu36 residue and the 
N5 loop residue Arg246 (Fig. 4C). The common IGHV1-24 
Phe56 residue in CDR-H2 forms a pi-cation interaction with 
Lys147 in the N3 loop (Fig. 4C). CM25 contains a 14-amino-
acid CDR-H3 loop that contributes 35% (261 Å2) of the total 
interface, including the AV aliphatic motif found in all but 
one of the convergent IGHV1-24 NTD-binding mAbs. Ala109 
and Val110 are buried at the interface in a binding pocket 
framed by the N3 and N5 loops. A comparison of CM25 with 
an extant structure of an IGHV1-24 NTD-binding antibody 
isolated by B cell cloning, 4A8 (4), revealed that the AV di-
peptide interaction is structurally conserved, and the 21 
amino-acid CDR-H3 of 4A8 extends along the outside of the 
NTD, contributing three additional contacts and 46% (415 Å2) 
of the total binding interface (Fig. 4D). Both structures show 
extensive contacts between the heavy chain of the Fabs and 
the NTD N3 and N5 loops. The Glu36-Arg246 salt bridge and 
an identical CDR-H2 contact between Phe56 and Lys147 are 
conserved in the 4A8-NTD interface. 
SARS-CoV-2 variants of concern contain mutations in the 
NTD N3 and N5 loops, including Y144/Y145Δ and K147E (UK
lineage B.1.1.7), W152C (California B.1.429), and 242-244Δ or
R246I (South Africa B.1.351). Alanine substitutions at several 
of these positions ablated binding or reduced affinity more 
than fivefold by public IGHV1-24 antibodies as exemplified 
by 4A8, CM17, and CM25 (Fig. 4E and fig. S9), a result con-
sistent with the CM25-NTD and 4A8-NTD structures. Addi-
tionally, we confirmed that an engineered N3-N5 double-
mutant and native B.1.351 (28) both evade neutralization by 
mAbs CM25 and 4A8 (Fig. 4F). Thus, mutations in SARS-CoV-
2 variants confer escape from public neutralizing anti-NTD 
antibodies. 
In conclusion, we find that the convalescent plasma IgG 
response to SARS-CoV-2 is oligoclonal and directed over-
whelmingly toward non-RBD epitopes in the S-ECD. This in-
cludes public, near-germline, and potently neutralizing 
antibodies against the NTD. The degree to which public anti-
NTD antibodies contribute to protection is likely related to 
their relative levels in plasma, which can be dominant in 
some individuals. Our finding that mutations present in cir-
culating SARS-CoV-2 variants can impair or ablate binding 
and neutralization by public anti-NTD antibodies may con-
stitute a mechanism of viral escape in a subset of the popula-
tion. Numerous other NTD mutations—which overlap with 
the structural epitope recognized by the public IGHV1-24 an-
tibody class—have been described in additional circulating 
variants, in laboratory escape mutants, and in immunocom-
promised patients (12, 29–33). 
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Fig. 1. Most plasma IgG antibodies bind non-RBD spike epitopes such as the NTD. (A) Affinity-purification 
using spike S-ECD (1) or RBD for subject P3. Plasma IgG lineage identities, binding specificity, and relative 
abundance were mapped via Ig-seq proteomics (14), facilitating recombinant plasma mAb characterization; 
anti-RBD (green); anti-S2 (blue); anti-NTD (red). (B) IgG ELISA binding (1:150 plasma dilution) to S-ECD alone, 
or in the presence of 50 μg/ml of RBD (S-ECD(RBD-)) or S-∆RBD deletion mutant. (C) Quantitative Ig-seq 
determination of anti-RBD and non-RBD IgG mAb abundance in early convalescent plasmas across four 
subjects. (D) Authentic virus neutralization (in duplicate) of the four most abundant plasma IgGs (CM29, CM30, 
CM31, CM32) from plasma lineages Lin.1, Lin.2, Lin.3, Lin.4 in subject P3. (E and F) Prophylactic protection of 
12-month-old BALB/c mice (n=5 per group) against lethal challenge with high dose (104 PFU) mouse-adapted
(MA10) SARS-CoV-2. Cocktail of non-RBD mAbs (200 μg per mouse) at 2:1:1 ratio reflecting their relative
plasma abundance. **P<0.005; ****P<0.0001, determined by one-way ANOVA with Dunnett’s multiple
comparisons test.
Fig. 2. Protective spike NTD-targeting antibodies are prevalent in COVID-19 convalescent plasma. (A) 
Temporal Ig-seq dynamics of the anti-S-ECD IgG repertoire at days 12 and 56 post-symptom onset. (B) Biolayer 
interferometry (BLI) sensorgrams to S-ECD ligand of anti-NTD mAbs CM17, CM25 (subject P2), and CM58 
(subject P4). (C) In vitro live virus neutralization (performed in duplicate). (D-F) In vivo prophylactic protection 
of 12-month-old BALB/c mice (n=5 per group) against high dose intranasal challenge (105 PFU) of mouse-
adapted (MA10) SARS-CoV-2. ***P<0.0007; ****P<0.0001, determined by one-way ANOVA with Dunnett’s 
multiple comparisons test.  
Fig. 3. Genetic basis of a shared, or public, class of IGHV1-24 plasma antibodies targeting the spike NTD. 
(A) IGHV usage of plasma antibodies in all subjects (n=4). (B) Comparative IGHV1-24 usage of anti-S-ECD (IgG-
ECD) and anti-RBD (IgG-RBD) plasma antibodies, or in depleted S-ECD affinity column flow through (IgG-
ECDnegFT) in all subjects (n=4). IgG-RSV/TIV: IgG specific to respiratory syncytial virus (RSV) or trivalent
influenza vaccine hemagglutinin HA1 (TIV) in healthy controls post-vaccination (n=6). **P<0.01, determined by
Mann–Whitney U test. (C) Sequence alignment of IGHV1-24 neutralizing anti-NTD IgGs from plasma (CM17,
CM25, and CM58) or from peripheral B cells (4A8 (4), 1-68 and 1-87 from a subject with ARDS (5), COV2-2199
(13), and COVA2-37 [mild disease subject]) (7). Arrows point to unique IGHV1-24 residues. Heatmap shows
recombinant mAb affinity (KD) and live-virus neutralization (IC50) for individual antibodies. (D) Competitive BLI
binding assay (“checkerboard competition”) of NTD-binding mAbs found in this study (CM17, CM25, CM58,
CM30, and CM31) and others (4A8 and 1-68). RBD-binding mAbs CM32 and CR3022 included for comparison.
Numbers refer to the shift, in nanometers, after second mAb binding to the preformed mAb–NTD complex.
Dashed box drawn to highlight strong competition (<0.1 nm shift) among 4A8 and three IGHV1-24 mAbs
examined in this study.
Fig. 4. Structural basis of public IGHV1-24 plasma antibodies, NTD mutations, and antibody 
escape. (A) Side and top views of the structure of CM25 Fab bound to S-ECD shown as cryo-EM 
density. (B) Focused refinement density revealing a VH-dominant mode of binding, with substantial 
contacts mediated by interactions between the three CDRs and the N3 and N5 loops of the NTD. (C) 
CDR-H1 interaction includes a salt bridge formed between the uniquely encoded Glu36 residue and 
the N5 loop residue Arg246; Phe56 unique residue in CDR-H2 forms a pi-cation interaction with 
Lys147 in the N3 loop. (D) The AV dipeptide interaction with the N3 and N5 loops of the NTD is 
structurally conserved between mAbs CM25 (red) and 4A8 (pink). (E) Normalized shift (Log2) in 
binding KD, as measured by differential BLI affinities for single Ala mutants and parental D614G spike 
protein. (F) Authentic virus neutralization of CM25 and 4A8 against WT, double S-N3/N5 loop 
mutants, and South Africa (SA) B.1.351 viral variant. 
